GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » LT-Debt-to-Total-Asset

CytoDyn (STU:296) LT-Debt-to-Total-Asset : 0.00 (As of Nov. 2024)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CytoDyn's long-term debt to total assests ratio for the quarter that ended in Nov. 2024 was 0.00.

CytoDyn's long-term debt to total assets ratio declined from Nov. 2023 (0.02) to Nov. 2024 (0.00). It may suggest that CytoDyn is progressively becoming less dependent on debt to grow their business.


CytoDyn LT-Debt-to-Total-Asset Historical Data

The historical data trend for CytoDyn's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn LT-Debt-to-Total-Asset Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 - 0.01 0.09 0.01

CytoDyn Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 - -

CytoDyn LT-Debt-to-Total-Asset Calculation

CytoDyn's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in May. 2024 is calculated as

LT Debt to Total Assets (A: May. 2024 )=Long-Term Debt & Capital Lease Obligation (A: May. 2024 )/Total Assets (A: May. 2024 )
=0.13/10.301
=

CytoDyn's Long-Term Debt to Total Asset Ratio for the quarter that ended in Nov. 2024 is calculated as

LT Debt to Total Assets (Q: Nov. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Nov. 2024 )/Total Assets (Q: Nov. 2024 )
=0.065/23.434
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoDyn  (STU:296) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


CytoDyn LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CytoDyn's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines